Press

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Nov 18 • 2 min read

Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. “The commencement of Novel Ketamine loaded Z-Pods is a pivotal advancement for administering Ketamine as…

MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights

Nov 16 • 3 min read

MindMed (Nasdaq: MNMD), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights (in USD) Cash Balance. Total assets as of September 30, 2021 were $178.6 million, including $145.9 million in cash, as compared to $85.6 million, including $80.1 million in cash, as of December 31, 2020 Net Cash Used in…

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

Nov 15 • 10 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the third quarter ended September 30, 2021, and provided its corporate update. “Following our IPO in June, we continue to see positive momentum. We have 11 therapeutic programs underway and…

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Nov 12 • 4 min read

MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND Diagnostics Inc. has executed a binding letter of intent with Revitalist Lifestyle and Wellness Inc. (CSE:CALM) (OTC:RVLWF) (FSE: 4DO) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics’ proprietary anti-inflammatory peptide…

Silo Pharma Reports Third Quarter Results and Operating Highlights

Nov 11 • 2 min read

Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business. Operating Highlights Entered sponsored research agreement with Columbia University to develop psychedelic therapeutics for Alzheimer’s Disease and received an option…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435